Biogen shortens name, expands ambitions in Alzheimer's, ALS

March 31, 2015 3:07 PM

8 0

Biogen shortens name, expands ambitions in Alzheimer's, ALS

Biogen Idec Inc has seen its market value quadruple in three years to more than $100 billion on the back of its successful multiple sclerosis drugs. Now it has new ambitions in its sights.

The Massachusetts-based company, which made headlines last week when it announced better-than-expected clinical trial results for its experimental Alzheimer's drug, aducanumab, said that it will drop Idec from its name as of Monday and adopt a new logo. The company merged with Idec Pharmaceuticals m...

Also read: Man pleads guilty in scamming $5M from government

Read more

To category page

Loading...